1 |
Gottlieb-Vedi E, Mattsson F, Lagergren P, Lagergren J. Annual hospital volume of surgery for gastrointestinal cancer in relation to prognosis. Eur J Surg Oncol 2019;45:1839-46. [PMID: 30904243 DOI: 10.1016/j.ejso.2019.03.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
|
2 |
Van Cutsem E, Hidalgo M, Canon J, Macarulla T, Bazin I, Poddubskaya E, Manojlovic N, Radenkovic D, Verslype C, Raymond E, Cubillo A, Schueler A, Zhao C, Hammel P. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. Int J Cancer 2018;143:2053-64. [DOI: 10.1002/ijc.31603] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 9.0] [Reference Citation Analysis]
|
3 |
Nishimura M, Matsukawa M, Fujii Y, Matsuda Y, Arai T, Ochiai Y, Itoi T, Yahagi N. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer. Gastrointest Endosc 2018;87:1126-31. [PMID: 29122598 DOI: 10.1016/j.gie.2017.10.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
|
4 |
McCarty TR, Rustagi T. New Indications for Endoscopic Radiofrequency Ablation. Clin Gastroenterol Hepatol. 2018;16:1007-1017. [PMID: 29081376 DOI: 10.1016/j.cgh.2017.10.023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
|